Journal
LEUKEMIA & LYMPHOMA
Volume 47, Issue 10, Pages 2062-2069Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190600733317
Keywords
acute myeloid leukemia; elderly; chemotherapy; behenoyl cytosine arabinoside
Categories
Ask authors/readers for more resources
The feasibility and effects of combination chemotherapy for very elderly patients with acute myeloid leukemia was examined in 65 patients ( including previous myelodysplastic syndrome) aged 76 years or morewith a performance status of 0 - 3. Induction chemotherapy was performed with 30 mg/m(2) daunorubicin on days 1 - 3, 150 mg/m(2) behenoyl cytosine arabinoside on days 1 - 7, and 70 mg/m(2) 6-mercaptopurine with 300 mg allopurinol taken orally on days 1 - 7 (BHAC-DM). The complete remission (CR) rate was 38.5%, whereas overall survival at 2 and 5 years was 22.0% and 4.7%, respectively. Two- and 5-year survival of CR patients was 41.8% and 11.2%, respectively. The relapse rate of the 25 CR patients was 64.0% and disease-free survival at 2 and 5 years was 21.0% and 11.2%, respectively. The therapy-related mortality rate at induction was 13.8%. BHAC-DM is feasible and effective for selected very elderly acute myeloid leukemia patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available